E.g., 23/07/2021
E.g., 23/07/2021

bioMérieux announces the CE marking of NEPHROCHECK® test on VIDAS®

Marcy l’Etoile, France – February 3rd , 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of the innovative NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).

03 February, 2021

AKI is a common complication, affecting between 7 and 18% of all hospitalized patients1 and up to 50% of critically ill patients2. The condition is associated with a 10-fold increase in hospital mortality and a higher rate of chronic kidney disease among post-op patients...

bioMérieux announces the CE marking of its molecular biology ARGENE® test for the simultaneous detection of SARS-CoV-2, influenza viruses A and B, and RSV and hMPV viruses

Marcy l’Etoile, France – December 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the real-time PCR (RT-PCR) detection of SARS-CoV-2: the SARS-COV-2 RESPI R-GENE® test has received CE marking and is now commercially available.  

16 December, 2020

This high-throughput test,...

The French bioproduction sector announces the creation of Campus Biotech Digital, a platform unique in the world for bioproduction training

An ambitious goal to develop the skills necessary for health independence

14 December, 2020

As part of its contract*, the French bioproduction sector is launching an ambitious training platform: Campus Biotech Digital. Unique in the world in the bioproduction field, it will help develop skills in this field to meet new technological challenges. Covering the entire bioproduction chain,...

Increased outlook for full-year 2020

Marcy l'Étoile, December 14,  2020 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2020.  

14 December, 2020

  • Full-year 2020 net sales are now expected to be around 18% at constant exchange rates and scope of consolidation and contributive operating income before non-recurring items  about €600 million. 
  • As a reminder, this...

BIOASTER, Université de Technologie de Compiègne, Hospices Civils de Lyon and bioMérieux formalize strategic collaboration to conduct Next Generation Sequencing technology evaluation in microbiology  

Lyon, December 2, 2020 - BIOASTER Microbiology Technology Research Institute announced a strategic partnership in the field of sequencing-based diagnostics in microbiology with the Université de Technologie de Compiègne (UTC), bioMérieux, a world leader of in vitro diagnostics and the Hospices Civils de Lyon.  

02 December, 2020

In the last decade, Next Generation Sequencing technologies have transformed the field of diagnostics in microbiology. BIOASTER is proud to partner with renowned academic and industrial actors to speed up transformation of this promising technology towards diagnostic tools useful for...

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.  

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.

16 November, 2020

The CE-marked SARS-CoV-2 R-GENE® test covers the above three sample types. This allows bioMérieux to address the recommendation issued by the French National Authority for Health (HAS) on September 18, 2020, which encourages the preferential use of saliva swabs to test symptomatic...

bioMérieux – Third-Quarter 2020 Business Review  

22 October, 2020

  • Organic growth of 19.4% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €2,266 million in sales
    • Up 17.5% as reported

AMSP partners with bioMérieux to facilitate supply of high-quality COVID-19 diagnostics

08 October, 2020

bioMérieux and the Africa Medical Supplies Platform (AMSP), have announced a new partnership to facilitate the supply of high-quality diagnostic solutions from the bioMérieux Pandemic Response Portfolio to African Union Member States.

The AMSP portal is an online marketplace that enables...

First-Half 2020 Results

02 September, 2020

  • Organic sales growth of 15.7% in first-half 2020:
    • €1,476 million in sales
    • Up 15.8% as reported
  • As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting with a...

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 July, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.),...